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ABSTRACT Immunogenicity of therapeutic proteins low-
ers patient well-being and drastically increases therapeutic
costs. Preventing immunogenicity is an important issue to
consider when developing novel therapeutic proteins and
applying them in the clinic. Animal models are increasingly
used to study immunogenicity of therapeutic proteins. They
are employed as predictive tools to assess different aspects
of immunogenicity during drug development and have
become vital in studying the mechanisms underlying
immunogenicity of therapeutic proteins. However, the use
of animal models needs critical evaluation. Because of
species differences, predictive value of such models is
limited, and mechanistic studies can be restricted. This
review addresses the suitability of animal models for
immunogenicity prediction and summarizes the insights in
immunogenicity that they have given so far.
KEY WORDS animalmodels.immunogenicity.therapeutic
proteins
ABBREVIATIONS
BLAST basic local alignment search tool
CD cluster of differentiation
HLA human leucocyte antigen
MHC major histocompatibility complex
PEG polyethylene glycol
PLGA poly(lactide-co-glycolide)
tPA tissue plasminogen activator
INTRODUCTION
Therapeutic proteins have revolutionized the treatment of
diseases such as diabetes, multiple sclerosis and rheumatoid
arthritis. An advantage of these drugs is that they do not
possess intrinsic toxicity due to harmful metabolites; they
a r eb r o k e nd o w nt oa m i n oa c i d s( 1). Furthermore,
therapeutic proteins are highly versatile. By recombinant
DNA techniques, monoclonal antibodies can be designed to
bind to various endogenous molecules in order to affect
their function. As a result, therapeutic proteins now make
up around 30% of the marketed drugs, and many more are
under development.
Immunogenicity is a major disadvantage of these protein
drugs. Almost all therapeutic proteins induce an antibody
response (2). While such an antibody response does not
necessarily cause severe side effects, clinical implications can
occur. Antibody formation may lead to a loss of efficacy,
neutralization of the endogenous counterpart or general
immune system effects (i.e., serum sickness like disease,
infusion reactions, anaphylaxis and anaphylactoid reac-
tions) (3–6). To prevent antibody-induced side effects and
thereby warrant better patient well-being and lower
therapeutic costs, it is important to treat patients with
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nicity (7,8). Animal models may be useful in developing
such low immunogenic drugs.
First, animal models are used as predictive tools during
drug development. The European Medicine Agency (EMA)
states that although predictive value of animal models is
considered low, they should be considered for selected
immunogenicity studies (9). In fact, the predictive value of
animal models depends on both the type of animal model
and what needs to be predicted.
Second, animal models can help to elucidate the
mechanisms underlying antibody responses against ther-
apeutic proteins (10). Such knowledge is vital in develop-
ing novel therapeutic protein products with low
immunogenicity.
The next sections focus on the suitability of various animal
models to predict immunogenicity and describe their use in
elucidating the mechanisms underlying immunogenicity.
ANIMAL MODELS AS TOOL TO PREDICT
IMMUNOGENICITY IN HUMANS
Although animal models are commonly used to assess drug-
related toxicity, there is still a debate on their suitability for
immunogenicity prediction during drug development. One
of the reasons for this debate is the difficulty of validation.
Although several studies using animal models in immuno-
genicity prediction are published (11–15), only a few have
bridged the gap between animals and human patients
(16,17). Most of the current studies only give an indication
on whether animals could be used to predict different
aspects of immunogenicity.
Classically, non-transgenic mice, rats and non-human
primates have been used. For proteins that are conserved
across species, non-human primates might have some
predictive value. Transgenic mouse models have been used
in immunogenicity prediction of proteins that are less
conserved between mice and humans (13,18).
The predictive value of animal models depends on the
similarity in processes underlying immunogenicity compared
to those in human patients. Because these processes are still
relatively unknown, we assume that animal models “closest”
tohumansintermsofgeneticbackgroundaremostpredictive.
According to this assumption, conventional animal models
such as rats and mice would have the least predictive value,
followed by transgenic animal models, and non-human
primates would have the highest predictive value.
Another important issue in immunogenicity prediction is
what needs to be predicted. Examples are the prediction of
1) neo-epitopes on modified proteins, 2) relative immuno-
genicity between products, 3) breaking of tolerance, 4)
immunogenicity in patients, 5) incidence of immunogenicity
in patients, and 6) clinical consequences of antibody
development (for example cross-reactive neutralizing anti-
bodies) (Table 1 for glossary). While some aspects might be
“easy” to predict, such as relative immunogenicity between
products, others, such as incidence of immunogenicity in
patients, are not (Table 2). In fact, incidence of immuno-
genicity in patients is predominantly determined during the
post-marketing stage. However, phase 3 studies might also
give an estimate on the incidence of immunogenicity in
patients when a product has relative high immunogenicity,
sufficient patients are included, and an immunological
response develops during the study duration. The next
sections will discuss the predictive potential of animal
models for different immunogenicity topics.
Conventional Experimental Animals
Most human therapeutic proteins are foreign proteins for
conventional animals such as mice and rats. These animals
will therefore develop a classical immune response against a
foreign molecule when treated with these foreign proteins,
while patients develop antibodies to these types of products
by another mechanism, most likely by breaking of B-cell
tolerance (10). Patients with Fabry disease, haemophilia
and other innate deficiencies who lack tolerance to these
products and may produce antibodies to alpha galactosi-
dase, factor VIII and other proteins via the classical
immune response are the exception (4).
Because the mechanisms underlying immunogenicity
differ between conventional animal models and humans,
the value of these models is limited. Most studies show that
conventional animal models over-estimate immunogenicity
in patients (19), making them unsuitable to predict
(incidence of) immunogenicity in patients. Several research-
ers have proposed that conventional models might be able,
for some proteins, to predict relative immunogenicity. Jaber
and colleagues used BALB/c mice to screen and select a
low immunogenic formulation of Rebif® (human interferon
beta-IFNβ 1a). The formulation with lowest immunogenic-
ity proved to be less immunogenic compared to the current
IFNβ 1a product at that time in a Phase I clinical trial (20).
Other researchers have also used BALB/c mice to assess
relative immunogenicity of IFNβ products (21).
However, conventional animal models are less likely to
predict clinical consequences of immunogenicity such as
development of neutralizing antibodies and presence of
neo-epitopes on modified proteins. This again is due to the
different mechanisms underlying antibody response. Be-
cause the therapeutic protein is foreign, the immune
response against it will involve T-helper cell recruitment,
affinity maturation, and neutralizing antibody development
(Table 1)( 22). It is therefore expected that conventional
animal models over-estimate neutralizing antibody devel-
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problems. Because therapeutic proteins are foreign to the
animals, multiple epitopes will be expressed. If protein
modification would lead to a new epitope, expression of this
epitope is likely overwhelmed by expression of the epitopes
that are already present on the unmodified protein. An
example is a mouse study performed by Katsutani and
colleagues (23). The aim of the study was to detect newly
exposed epitopes on an analogue of human tissue plasmin-
ogen activator (mt-PA6), compared to native sequence
human tissue plasminogen activator (tPA). Their results
suggest that the antibodies formed in the mt-PA6-treated
mice are directed mainly against epitopes present in the
native sequence human tPA that have not been altered in
the analogue
In summary, there are some suggestions that conven-
tional animal models could assess relative immunogenicity
between products (also discussed later on). However, these
models have no predictive value for assessing (occurrence
of) immunogenicity in humans, neutralizing antibodies or
neo-epitopes.
Transgenic Immune Tolerant Animals
To overcome a classical immune response against “foreign”
therapeutic proteins in conventional animal models, immune-
tolerant transgenic mice that express the protein of interest
have been developed. The mechanisms underlying antibody
formation against the corresponding therapeutic protein are
thereforeexpectedtobesimilartothemechanismsinhumans.
One of the first immune-tolerant transgenic mouse
models for immunogenicity studies was the human tPA
mouse model developed by Stewart and colleagues in 1989
(24). This transgenic mouse model was used to evaluate the
induction of neo-epitopes by amino acid substitution of
human tPA. When challenged with a form of tPA in which
a single amino acid was substituted, the transgenic mice
produced antibodies recognizing human tPA. The authors
therefore concluded that modifying therapeutic proteins
could have immunological consequences in patients. An-
other transgenic mouse model developed to assess the
induction of new epitopes by protein modification was the
human insulin-expressing mouse model (25). This model
Table 1 Glossary
Term Explanation
Antigenicity The ability of a compound (e.g., a therapeutic protein) to bind to components of the adaptive immune system
(e.g., antibodies).
Immunogenicity The capability of a compound (e.g., a protein) to induce an immune response (e.g. anti-drug antibodies).
Epitope A specific part of a compound (e.g., a peptide sequence in a protein) that is recognized by a product of the
immune system (e.g., an antibody).
Neo-epitope A novel epitope that is formed due to protein modification, such as amino-acid substitution, or chemical or
physical degradation.
Non-neutralizing antibody An antibody that binds to the therapeutic protein but does not affect its intrinsic activity/receptor binding;
however, it may change its pharmacokinetics and thus affect therapeutic efficacy. Also referred to as
binding antibody.
Neutralizing antibody An antibody that binds to the active site of the therapeutic protein and thereby inhibits its function.
As a result, efficacy will be diminished, and therapy failure can occur.
Tolerance Immunological non-reactivity to a therapeutic protein, usually resulting from previous exposure to the endogenous
counterpart of that protein.
Table 2 Predictive Potential of Animal Models for Different Aspects of Immunogenicity
Predictive potential for
Animal model Neo-epitopes Relative
immunogenicity
Breaking of tolerance Immunogenic
potential in
patients
Incidence of
immunogenicity
Clinical consequences
of antibody
development
Conventional No (10) Yes (11)N o N o ( 12)N o ( 12) Unlikely
Transgenic Yes (13,14) Yes (15) Yes (16) Unlikely No (15)?
Non-human
primates
In theory yes (10),
but depends on
protein
Yes (10,17) In theory yes, but
depends on protein
(16,17)
Possibly
(17,18)
Unlikely Possibly (19)
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insulin analogues (12). The authors found that the
incidence of antibodies against insulin correlated with an
increase in the number of substitutions on the insulin
molecule. They therefore state that transgenic mice could
be used to characterize the relative immunogenicity of
different protein analogues. These studies on tPA and
insulin show that transgenic mouse models are capable of
detecting neo-epitopes as a result of protein modification.
Transgenic mouse models have also been used to assess
relative immunogenicity. One of these models is the human
interferon beta transgenic mouse model (13,26). Our
research group has shown that the interferon beta product
with highest immunogenicity in patients (Betaseron) also
has highest immunogenicity in the mouse model (13).
However, we observe almost no difference in immunoge-
nicity between Avonex and Rebif, although their immuno-
genicity profile in patients differs. (27). Also, the incidence
of immunogenicity in the mice does not correspond to the
incidence in patients.
In another study, we looked at whether conjugation of a
PEG group to the interferon beta protein would affect
antibody response. PEGylation is a commonly used modifi-
cation to improve the pharmacokinetic profile of a protein
and is not primarily intended to decrease its immunogenicity.
None of the PEGylated and non-PEGylated interferon-beta-
treated transgenic mice developed an antibody response (13).
Apparently, conjugation of PEG to interferon beta does not
affect immunogenicity for this protein. Lee and colleagues
have used transgenic immune-tolerant mice to assess
whether a formulation of human growth hormone (GH)
containing PLGA microspheres would break tolerance for
GH (28). They showed that both the microsphere-free and
microsphere-containing formations did not evoke an anti-
body response in the transgenic mice. The authors conclud-
ed that in the case of homologous proteins like GH, PLGA-
containing formulations do not induce a break of tolerance
or act as adjuvant. Fradkin and colleagues have used a
similar GH transgenic mouse model to study if an aggregate-
containing formulation would be able to induce an antibody
response. They showed that none of the aggregate-
containing solutions was able to induce antibody formation
(29). This contrasts a finding reported in the study by Lee, in
which GH aggregates did appear to induce an antibody
response in their transgenic mice (unpublished finding by J.
Cleland, E. Duenas and A. Jones). The type of aggregate
and experimental setup would have contributed to this
discrepancy.
Besides transgenic mouse models that express human
proteins resembling therapeutic proteins, the use of HLA
transgenicmicealsoincombinationwiththeimmune-tolerant
models has been suggested to predict immunogenicity. HLA
transgenicmiceexpresshumanMHCandshouldintheorybe
able to present similar epitopes as patients. Combined
transgenics expressing MHC and the human protein of
interest might also be useful to answer the question whether
the breaking of tolerance is restricted to certain HLA types.
In summary, transgenic animal models can be used to
predict neo-epitopes, relative immunogenicity, and break-
ing of tolerance. However, they are likely less suitable to
predict the incidence of immunogenicity or clinical effect of
antibody formation. HLA transgenics may be an interesting
additional tool to study whether the immunogenic response
is HLA restricted.
Non-Human Primates
Because the proteins of humans and non-human primates
show a high degree of homology, non-human primates
should be tolerant for most human proteins. The mecha-
nisms underlying their antibody response would therefore
likely be similar to the human response.
The toxicology research group of Eli Lilly, including
Zwickl and Wierda, has performed several experiments to
study the translational value of rhesus monkeys in immu-
nogenicity research (11,14,15,17). In one study, rhesus
monkeys were treated with recombinant methionyl-human
growth hormone (hGH), pituitary-derived hGH or recom-
binant natural sequence hGH in order to assess relative
immunogenicity between products. Only 4 out of 190
amino acids differ between the human and monkey protein
(28). However, it has been suggested that rhesus monkeys
are not tolerant for human GH (28). The authors found
antibody responses in, respectively, 81%, 69% and 5–23%
of the monkeys, which correlates with clinical observations
in terms of relative immunogenicity (17). The authors
therefore conclude that rhesus monkeys might be useful in
predicting relative immunogenicity of some human pro-
teins. In contrast, the absolute incidence of antibody-
positive individuals, in the case of GH, was not predicted.
In another study, the same research group compared
immunogenicity of tissue plasminogen activator (tPA) and a
plasminogen activator analogue (mt-PA6) in rhesus monkeys
(15). Both native-sequence protein and mt-PA6 expressed
similar low immunogenicity in the monkeys. The authors
concluded that mt-PA6 would be very unlikely to present a
serious immunogenic risk in humans, as the native sequence
gives an antibody response in only a small number of
patients who receive a single administration. In a more
recent experiment in which chimpanzees were treated with t-
PA, the authors also suggest that apes have predictive value
in terms of neo-epitope detection (23). They show that
modifications of the native PA do not lead to neo-epitopes
and increased antibody response in chimpanzees, and
therefore claim that these modified proteins are unlikely to
give an antibody response in patients. Besides neo-epitope
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to study (neo-) epitopes in insulin. Rhesus monkeys were
immunized with three forms of insulin: native sequence
human insulin, LysPro insulin and porcine insulin. Of all 12
monkeys included in the experiment, one showed low levels
of pretreatment anti-insulin antibodies and later on devel-
oped higher, but still low, levels of anti-insulin antibodies
(14). These results show that alterations to amino-acid
sequence of human insulin (LysPro insulin) do not induce
neo-epitopes in rhesus monkeys. Similar is found in patients:
native sequence insulin and LysPro insulin do not differ in
immunogenicity (30).
Besides having potential predictive value in relative
immunogenicity assessment and neo-epitope determination,
non-human primates might also predict clinical effect of
antibody formation, i.e. neutralizing auto-antibodies. In the
report of the FDA meeting of the biological response
modifiers advisory committee in 1999 (16), it is shown that
non-human primates predicted an autoimmune reaction to
thrombopoietin that was also observed clinically.
An example in which non-human primates are not
suitable to predict (incidence of) immunogenicity in patients
is interleukin 3. Gunn and colleagues used rhesus monkeys
to assess immunogenicity of recombinant human
interleukin-3 (31). All monkeys formed neutralizing anti-
bodies against recombinant human interleukin 3, while
~5% of patients form antibodies. Interestingly, homology
between the interleukin 3 primary sequence of humans and
rhesus monkeys is 93% (alignment via BLAST).
It appears that similarity in amino-acid sequence does
not guarantee that the animal model will display similar
immunogenicity compared to patients. Other factors such
as experimental setup, assays, disease state, or other
(immune-related) genes could all contribute to a different
immunogenicity profile (32).
In summary, non-human primates have predictive value
for some therapeutic proteins; they may be useful to assess
relative immunogenicity, neo-epitopes and development of
neutralizing (cross reactive) antibodies.
Overall, animal models appear to have predictive
potential when assessing relative immunogenicity, neo-
epitopes or breaking of tolerance. The studies described
show that the predictive value is, in addition to the model
and research question, also dependent on the protein. Only
a few of the results from animal models have been clinically
validated (or not), which makes it hard to draw conclusions
on their actual predictive value.
WHY ARE ANIMAL MODELS LIMITED?
Transgenic mice expressing the protein of interest are often
advocated as the preferred in vivo model to predict
immunogenicity of therapeutic proteins. These models
have the advantage of being immune tolerant, and mouse
experiments encounter less ethical constraints compared to
experiments using non-human primates. However, as
shown in the previous section, these transgenic mice still
have their limitations.
One of the reasons why animal models are limited in
immunogenicity prediction is because the mechanisms
underlying immunogenicity are still unknown and there
may be important differences between the human and
animal response. For example, if a therapeutic protein
elicits a T-cell-dependent immune response (10), differences
in T-cell subsets or MHC molecules between species might
contribute to different immunogenicity. Also, if a therapeu-
tic protein induces an immune response in a T-cell-
independent manner (10), differences in B-cell subsets or
dendritic cells could introduce species-dependent immuno-
genicity. In many cases, also patients have an altered
immune system due to their disease or therapy.
Another reason for species-related immunogenicity could
be a lack of genetic diversity of the animals. The animals used
forimmunogenicitytestingareofteninbredandthereforehave
almost identical genetic make-up, which contrasts the genetic
diversity between humans. As genetic makeup has been
implied in immunogenicity (32,33), constriction in genetic
variability of the animals can limit immunogenicity prediction
for human populations. Even more, mice can have a genetic
background that renders them insensitive to form an antibody
response against certain therapeutic proteins (12).
Besides the animal model itself, the experimental setup will
also affect predictive value. Differences in dose, immunization
route, frequency of administration and impurities in the
formulation have the potential to affect immunogenicity and
itsassessment(32). Moreover, with respect to product quality,
preclinical protein products which are used in animal studies
do not always reflect the final products used to treat patients.
Another difficulty in translating animal results to human
patients is a difference between labs in antibody assays that
are used. These differences hamper comparison of results
gained in different labs and therefore compromise predictive
value of animal models. In patient research, several
initiatives have begun to standardize antibody assays and
thus improve comparability (34). Adjusting the antibody
assays used in animal research to these standardized assays
would likely improve predictive value of the models.
ANIMAL MODELS TO STUDY THE MECHANISMS
UNDERLYING IMMUNOGENICITY
OF THERAPEUTIC PROTEINS
Knowing why and how therapeutic proteins induce an
antibody response will be key for the development of
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peutic proteins with low immunogenicity. They may help to
avoid a particular type of aggregate, design the optimal
formulation, delete a certain epitope, and tailor glycosyla-
tion and other modifications. Transgenic animal models are
an important tool in studying the immune mechanisms
underlying immunogenicity of therapeutic proteins.
A major finding in these models is aggregates as a risk
factor for immunogenicity. All protein formulations
contain at least low levels of aggregates (35), but it is
not known which type of aggregates at what level pose a
risk. The first study looking into the possible impact of
aggregates on immunogenicity using transgenic mice was
performed by Braun and colleagues. They found that
interferon alpha aggregates were able to induce an
antibody response in transgenic immune-tolerant mice,
while the monomer was not (36). Hermeling et al.( 18,37)
continued on this data and studied which types of
interferon alpha aggregates would be most immunogenic.
Interestingly, aggregates with native-like structure
appeared to have the highest immunogenicity. These
oxidation-induced aggregates showed a dose-dependent
antibody response (37), whereas oxidation alone did not,
showing that the presence of aggregates, and not oxidation
p e rs é ,w a sc r u c i a lf o ri m m u n o g e n i c i t y( 18). Also for
recombinant human interferon beta such transgenic animal
studies have been performed (22). A formulation with non-
covalent aggregates induced a higher antibody response than
a reformulated product with substantially less aggregates. A
formulation with aggregates lacking native epitopes was
poorly immunogenic. Rifkin and colleagues also showed that
lowering aggregate content in interferon beta lowers
immunogenicity in mice (38). The high immunogenicity of
aggregated interferon beta-containing products in the
transgenic mice corresponds to what is observed in patients
with multiple sclerosis. Patients treated with therapeutic
interferon beta with highest aggregate content (Betaferon)
have the highest antibody responses (27). The data on
immunogenicity of aggregates gives some insight into the
molecular mechanisms underlying immunogenicity of ther-
apeutic proteins, in particular interferon alpha and beta.
Aggregates contain repetitive epitopes that might mimic
viruses or bacteria. By binding and cross linking the B-cell
receptors, such structures can induce antibody formation in
a T-independent manner (10).
Animal models have given some insight into T-cell
involvement. A recent study using the human interferon
beta transgenic mice showed that no immunological
memory was formed against aggregated human interferon
beta, despite a clear antibody response against the protein
(22). This correlates with clinical observations in which the
antibody response against therapeutic interferon beta does
not appear to induce immunological memory (39). Absence
of immunological memory supports a lack of T-helper cell
involvement, and possibly indicates a T-cell-independent
mechanism involved in the antibody response. However, a
study by Sauerborn et al. (unpublished data) in which all
CD4 positive T-cells were depleted shows that T-cells are
necessary for antibody formation. This corresponds to the
finding that in animals (and humans) antibody isotype
switching does take place, i.e. IgG subclasses are present in
plasma. Isotype switching is usually a result of T-helper cell
involvement and therefore contradicts a T-cell-independent
immune response, although isotype switching has been
described in absence of T-helper cell function (40).
The data so far in transgenic immune-tolerant mice are
still ambiguous, and the immune mechanisms underlying
immunogenicity of therapeutic proteins are neither a
classical immune response against a foreign protein nor a
clear T-cell-independent activation of B-cells (10). Future
studies on T-cell subsets and cytokine profiles should shed
more light on the cells involved in the antibody response.
A tantalizing idea would be to gain enough knowledge
on the mechanisms underlying immunogenicity of thera-
peutic proteins to be able to induce, or maintain, tolerance
against therapeutic proteins.
CONCLUSION
Animal models can be valuable in predicting immunoge-
nicity of therapeutic proteins. However, the predictive
value depends on the model and the research question.
Additional treatment- and disease-related factors could
additionally influence predictive value. Although more
and more studies using animal models as predictors are
published, the predictive value of animal models still needs
to be fully established. In addition, animal models have
proven valuable in elucidating the immune mechanism
underlying immunogenicity and will certainly substantiate
their value during future experiments.
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